Comparative Pharmacology
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus XELODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus XELODA.
FLUDARABINE PHOSPHATE vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine phosphate is a purine analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to apoptosis in lymphocytes.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
25 mg/m2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Terminal half-life of 2-fluoro-ara-A is approximately 20 hours (range 10–30 hours). Clinical context: accumulation occurs with repeated dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Renal excretion of the active metabolite 2-fluoro-ara-A accounts for approximately 60% of drug elimination. Biliary/fecal elimination is minimal (<5%).
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category D/X
Category C
Antimetabolite
Antimetabolite